Date: 18 Nov 2012
Pharmaceutical care program for type 2 diabetes patients in Brazil: a randomised controlled trial
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Background Brazilians with type 2 diabetes require action to improve haemoglobin A1C levels considering the fact that approximately 73 % of them have poor glycaemic control. Evidence has shown the potential benefits of pharmaceutical care programs in type 2 diabetes patients. Objective To evaluate the effect of a pharmaceutical care program on blood glucose, blood pressure and lipid profile in hyperglycaemic patients undergoing drug treatment for type 2 diabetes. Setting Six primary care units of the Brazilian public health system, Ouro Preto, Brazil. Method An open, randomised, controlled clinical trial was conducted for 6 months. Subjects aged 18 years or older who were using oral antidiabetic medications and presenting haemoglobin A1C levels ≥7 % were randomly assigned to receive only usual health care or usual health care plus pharmaceutical intervention. Main outcome measure Haemoglobin A1C. Results A total of 129 subjects were enrolled, and 100 patients completed the study. Compared to the control group (n = 50), the intervention group (n = 50) showed a significant reduction of haemoglobin A1C (−0.6 vs 0.7 %, p = 0.001), fasting plasma glucose, total cholesterol, LDL cholesterol, triglycerides and systolic blood pressure and a significant increase in HDL cholesterol and the use of lipid-modifying agents and platelet aggregation inhibitors. Conclusions This study suggests that a pharmaceutical care program may provide important contributions to reduce haemoglobin A1C in type 2 diabetes patients. Moreover, the promotion of the rational use of drugs may be better achieved in a context of pharmaceutical care programs in Brazil.
Sociedade Brasileira de Diabetes (SBD). Diretrizes da Sociedade Brasileira de Diabetes. [cited 2012 18 Jul]; Available from: http://www.diabetes.org.br/attachments/diretrizes09_final.pdf.
Brasil. Saúde Brasil 2009: uma análise da situação de saúde e da agenda nacional e internacional de prioridades em saúde. [cited 2012 18 Jul]; Available from: http://portal.saude.gov.br/portal/arquivos/pdf/29_11_10_saude_brasil_web.pdf.
World Health Organization. The role of the pharmacist in the health care system. Vancouver, Canada; 1997. [cited 2012 18 Jul]; Available from: www.opas.org.br/medicamentos/site/UploadArq/who-pharm-97-599.pdf.
Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47:533–43.PubMed
Neto PRO, Marusic S, Lyra-Júnior DP, Pilger D, Cruciol-Souza JM, Gaeti WP, et al. Effect of a 36-month pharmaceutical care program on coronary heart disease risk in elderly diabetic and hypertensive patients. J Pharm Pharmaceut Sci. 2011;14:249–63.
Correr CJ, Pontarolo R, Wiens A, Rossignoli P, Melchiors AC, Radominski R, et al. Economic evaluation of pharmacotherapeutic follow-up in type 2 diabetes mellitus patients in community pharmacies. Arq Bras Endocrinol Metab. 2009;53:825–33.CrossRef
Cid AS. Avaliação da efetividade da atenção farmacêutica no controle da hipertensão arterial. Dissertação (Mestrado em Ciências Farmacêuticas). Universidade Federal de Ouro Preto, Ouro Preto; 2008.
World Health Organization. ATC/DDD Index 2010. [cited 2012 18 Jul]; Available from: http://www.whocc.no/atc_ddd_index/.
Friedewald WT, Levi RI, Fredrickson DS. Estimation of the concentration of low density lipoproteins cholesterol in plasma without use of the ultracentrifuge. Clin Chem. 1972;18:499–502.PubMed
American Diabetes Association. Standards of medical care in diabetes—2011. Diabetes Care. 2011;34(Suppl. 1):S11–61.CrossRef
Cipolle RJ, Strand LM, Morley PC. Pharmaceutical care practice: the clinician’s guide. 2nd ed. New York: McGraw-Hill; 2004.
Fera T, Bluml BM, Ellis WM. Diabetes ten city challenge: final economic and clinical results. J Am Pharm Assoc. 2009;49(3):383–91.CrossRef
Ivama AM, Noblat L, De Castro MS, De Oliveira NVBV, Jaramillo NM, Rech N. Consenso Brasileiro de atenção farmacêutica. Brasília: PAHO/WHO; 2002.
Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med. 2001;135:825–34.PubMed
- Pharmaceutical care program for type 2 diabetes patients in Brazil: a randomised controlled trial
International Journal of Clinical Pharmacy
Volume 35, Issue 1 , pp 79-86
- Cover Date
- Print ISSN
- Online ISSN
- Springer Netherlands
- Additional Links
- Diabetes mellitus
- Diabetes type 2
- Pharmaceutical care
- Randomised controlled trial
- Industry Sectors
- Author Affiliations
- 1. Post-Graduate Program in Pharmaceutical Sciences, School of Pharmacy, Federal University of Ouro Preto, Ouro Preto, Brazil
- 2. Department of Pharmacy, School of Pharmacy, Federal University of Ouro Preto, Rua Costa Sena 171, Ouro Preto, MG, Centro 35400-000, Brazil
- 3. Department of Pharmaceutical Products, School of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Brazil
- 4. Department of Clinical Analysis, School of Pharmacy, Federal University of Ouro Preto, Ouro Preto, Brazil